What the FDA labels say about taking them together
Buprenorphine and cobicistat
Cobicistat's FDA label of February 10, 2026 names buprenorphine in its drug interactions section; the buprenorphine labels PlainMeds reads (4) do not name cobicistat. The cobicistat label: “A dose adjustment for buprenorphine, buprenorphine/naloxone, or methadone may be needed.”
Check it at the source: the buprenorphine FDA label on DailyMed (effective June 5, 2026); the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.).
What does the buprenorphine label say about cobicistat?
Buprenorphine's label (effective June 5, 2026) and its 3 other brand-application labels do not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Buprenorphine HCl), SpecGx LLC, effective June 5, 2026 (SPL set b60d514d-a88a-4fa2-a5b0-30ac29e04973), via openFDA; the full label on DailyMed
What does the cobicistat label say about buprenorphine?
Cobicistat label, drug interactionsA dose adjustment for buprenorphine, buprenorphine/naloxone, or methadone may be needed.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Buprenorphine | Cobicistat | |
|---|---|---|
| Labeled for | Opioid use disorder, Pain | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.277 per tablet 2 mg tablet sl | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once